GALEN ANACARE consensus statement: Potential of omalizumab in food allergy management.

Publication

GALEN ANACARE consensus statement: Potential of omalizumab in food allergy management.

Journal Paper/Review - Nov 1, 2024

Zuberbier Torsten, Muraro Antonella, Nurmatov Ulugbek, Arasi Stefania, Stevanovic Katarina, Anagnostou Aikaterini, Bonaguro Roberta, Chinthrajah Sharon, Lack Gideon, Fiocchi Alessandro, Le Thuy-My, Turner Paul J, Alvaro-Lozano Montserrat, Angier Elizabeth, Barni Simona, Bégin Phillippe, Ballmer-Weber Barbara, Cardona Victoria, Bindslev-Jensen Carsten, Cianferoni Antonella, de Jong Nicolette, de Silva Debra, Deschildre Antoine, Dunn Galvin Audrey, Ebisawa Motohiro, Fleischer David M, Gerdts Jennifer D, Giovannini Mattia, Gradman Josefine, Halken Susanne, Arshad Syed Hasan, Khaleva Ekaterina, Lau Susanne, Loh Richard, Mäkelä Mika, Marchisotto Mary Jane, Morandini Laura, Mortz Charlotte G, Nilsson Caroline, Nowak-Wegrzyn Anna, Podestà Marcia, Poulsen Lars K, Roberts Graham, Rodríguez Del Río Pablo, Sampson Hugh A, Sanchez Angel, Schnadt Sabine, Smith Peter Kenneth, Szajewska Hania, Mitrevska Natasa Teovska, Toniolo Alice, Venter Carina, Warner Amena, Wong George K C, Wood Robert, Worm Margitta

Citation

Zuberbier T, Muraro A, Nurmatov U, Arasi S, Stevanovic K, Anagnostou A, Bonaguro R, Chinthrajah S, Lack G, Fiocchi A, Le T, Turner P, Alvaro-Lozano M, Angier E, Barni S, Bégin P, Ballmer-Weber B, Cardona V, Bindslev-Jensen C, Cianferoni A, de Jong N, de Silva D, Deschildre A, Dunn Galvin A, Ebisawa M, Fleischer D, Gerdts J, Giovannini M, Gradman J, Halken S, Arshad S, Khaleva E, Lau S, Loh R, Mäkelä M, Marchisotto M, Morandini L, Mortz C, Nilsson C, Nowak-Wegrzyn A, Podestà M, Poulsen L, Roberts G, Rodríguez Del Río P, Sampson H, Sanchez A, Schnadt S, Smith P, Szajewska H, Mitrevska N, Toniolo A, Venter C, Warner A, Wong G, Wood R, Worm M. GALEN ANACARE consensus statement: Potential of omalizumab in food allergy management. Clin Transl Allergy 2024; 14:e70002.

Type

Journal Paper/Review (English)

Journal

Clin Transl Allergy 2024; 14

Publication Date

Nov 1, 2024

Issn Print

2045-7022

Pages

e70002

Brief description/objective

Immunoglobulin E (IgE)-mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti-IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE-mediated food allergies by the US Food and Drug Administration (FDA). This GALEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE-mediated food allergies, based on a systematic review and meta-analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE-mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation.